About 100 reports
- BUSINESS SEGMENTATION BY REVENUE
- GILEAD SCIENCES
GS-##, a therapeutic vaccine, generates T-cell immune responses and acts against cells containing HBV antigens in combination with antiviral therapy.
PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025
- 6.6 OTHER BRANDED DIRECT-ACTING ANTIVIRALS
- 7.2 REDUCING THE OVERALL COST BURDEN OF DIRECT-ACTING ANTIVIRAL TREATMENT
- Global hepatitis C therapeutics market 2014-2019 ($ millions)
- Global hepatitis B therapeutics market 2014-2019 ($ millions)
However, choice is limited when it comes to direct-acting antivirals.
Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape
- Increasing Awareness and Accessibility of Next-Generation Direct-Acting Antivirals...
- summarizes the most recently recommended treatment regimens for HCV infection in
The company has also signed a deal worth $## billion with Moderna for its messenger RNA therapeutics platform in developing new antiviral vaccines and passive immunity therapies.
Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations
- 2.2 Pipeline Dominated by Direct-Acting Antivirals
- 2.3 Diverse Range of Host-Targeting and Direct-Acting Antivirals in First-in-Class...
- GILEAD SCIENCES IN LIVER CIRRHOSIS THERAPEUTICS MARKET SOVALDI
- To grow a diversified business To simplify the operating model to increase efficiency
The acquisition includes Novira' s antiviral products, including its lead candidate, NVR ##-##.
Applications Covered: - Hepatitis-B antivirals - Hepatitis-C antivirals - Herpes virus - HIV antivirals - Influenza - Other Applications o Pneumonia o Flu End-Users Covered: - Ambulatory Surgical Centers - Clinics - Hospitals Distribution Channels covered: - Hospital Pharmacy Sto
- Brazil: Fastest Growing Therapy Classes (ATC 3)
BRAZIL IMS Pharmaceutical Pricing & Reimbursement Concise Guide Published March 2017 The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions.
- SHARE OF INFECTIOUS DISEASES MARKET IN PHARMACEUTICAL MARKET IN CHINA 2015
It has direct antiviral activity in tissue culture against RNA viruses.
Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
- depicts the treatment algorithm recommended by WHO for the management of chronic hepatitis...
- Management of Hepatitis B Infection
MARKET OVERVIEW.............. ## Antivirals.............. ## Table ##: Antiviral Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others ## Infectious Disease Drugs.............. ## Table ##: Infectiou
Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
- 6.3.1 Phase II
- 3. Hepatitis C - Approved Drugs Sales & Forecast
The study will examine the hypothesis that pretreatment viral testing will identify patients who will respond to antiviral therapy with Telaprevir.
Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024
Interferon and Antiviral ##. ##. ##. ##.
MARKET OVERVIEW.............. ## Antiviral Drugs.............. ## Table ##: Antiviral Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others ## Table ##: Hepatitis C Market by Category Worldwide (2015) - Per
Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics
- VIRAL INFECTIONS THERAPEUTICS MARKET, GLOBAL, FORECAST ANNUAL REVENUES FOR
- 18.104.22.168 Failure Rates by Molecular Target
ANTIVIRAL THERAPY TARGETING VIRAL POLYMERASE.
- Trial Results
Recurrent D##BB Antivirals ATC Classification Target Patient Details Age Gender Accept Healthy Volunteer(s) Subject(s) Type Participant Criteria (Inclusion) ## Years and older Both No Glucocorticoid Receptor (GR); Viral DNA Polymerase Participant Criteria (Exclusion) Generally good health
- 3.4.2 ANTIVIRAL THERAPY
- RECOMMENDED ANTIVIRAL REGIMENS FOR THE MANAGEMENT OF GH IN IMMUNOCOMPETENT PATIENTS
- HIV-1 INFECTION THERAPEUTICS, GLOBAL, SUSPENDED CLINICAL TRIALS, 2014*
- Trial Results
In preclinical studies, doravirine showed potent antiviral activity against HIV-##.
- Drug Details
- Contact Detail(s)
It is an antiviral medicament employed in combination therapy along with other antiviral drugs for the treatment of children and adults aged above two years, who are infected with Human Immunodeficiency Virus type ##.